Kalite Pharmaceuticals Private Limited
Founded in 2015 and headquartered in Delhi, India.
2015 | Delhi (India) | Active
Kalite Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth 11.52%
- Ebitda 27.56%
- Net Worth -68.50%
- Total Assets -38.92%
About Kalite Pharmaceuticals
Kalite Pharmaceuticals Private Limited (KPPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 May 2015 (Nine years and nine months 18 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Bipin Kumar, Alok Singh, and Arun Sinha serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909DL2015PTC279920
- Company No.
279920
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 May 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Trading
Who are the key members and board of directors at Kalite Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bipin Kumar  | Director | 20-Mar-2021 | Current |
| Alok Singh | Director | 11-May-2021 | Current |
| Arun Sinha | Director | 20-Sep-2023 | Current |
Financial Performance of Kalite Pharmaceuticals.
Kalite Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 11.52% increase in profit. The company's net worth observed a substantial decline by a decrease of 68.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kalite Pharmaceuticals?
In 2017, Kalite Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Alvis Biotech India Private Limited
Bipin Kumar and Arun Sinha are mutual person
- Alvis Himalaya Biotech India Private Limited
Arun Sinha is a mutual person
- Alvis Herbotech Private Limited
Arun Sinha is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kalite Pharmaceuticals?
Unlock and access historical data on people associated with Kalite Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kalite Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kalite Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
